Drug
Brenetafusp clinical trials
- studies test it
- 3
- open now
- 2
- in phase 3
- 1
- first study started
- 2020
Keep track of what changes. Save the brenetafusp studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
Immunocore Ltd (2) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Pembrolizumab (1) · Antibodies, Monoclonal (1) · Tebentafusp (1) · Bevacizumab (1)
Studies
Open first, then newest update. How each study uses brenetafusp is read from its arms, and is right about nine times in ten.
Testing it · 3
- Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare CancersNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07686367Written as Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)RecruitingPhase 3Immunocore LtdNCT06112314Written as Brenetafusp
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsActive, not recruitingPhase 1/2Immunocore LtdNCT04262466Written as Brenetafusp
Codes
What other systems call brenetafusp · ClinicalTrials.gg INT015073
- UNII (FDA) 5GK14JY4JEBRENETAFUSPOne source FDA
- NCI Thesaurus C199026BrenetafuspOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5GK14JY4JE | BRENETAFUSP | One source FDA |
| NCI Thesaurus | C199026 | Brenetafusp | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.